APP and schizophrenia: Briefly, APP was strongly associated with a higher daily dose (12.1 mg/d of a risperidone equivalent dose; RISeq) and a greater reduction in cognitive function measured using the z score of the Brief Assessment of Cognition in Schizophrenia, a scale used to assess cognitive function, in comparison to APM (4.2 mg/d of RISeq) [73].